We introduced the interleukin-12 (IL-12) gene into mouse renal cell carcinoma (RenCa) cells to develop a tumor vaccine and to examine mechanisms of tumor rejection. IL-12-secreting RenCa (RenCa/IL-12) cells were completely rejected when implanted into syngeneic BALB/c but not athymic nude mice, suggesting that T cells were involved in this antitumor effect. 
I
nterleukin-12 (IL-12), formerly termed natural killer (NK) cell-stimulatory factor 1 or cytotoxic lymphocyte maturation factor, 2 exerts a variety of biological effects on T cells and NK cells. These include the ability to stimulate the production of interferon-␥ (IFN-␥) and other cytokines from peripheral blood T cells and NK cells, 3, 4 to enhance the lytic activity of NK cells, 1, 3 to promote the expansion of activated NK cells and activated T cells, 5 and to induce a primarily T helper 1 response in vitro 6 as well as in vivo. These biological activities of IL-12 indicate that this factor should have multiple antitumor effects. IL-12 actually demonstrates therapeutic activity in various murine tumor models. 7, 8 In fact, the antitumor effect of IL-12 is so striking that even established tumors are eradicated by its systemic administration. However, the systemic administration of IL-12 caused dose-dependent toxicity in human clinical trials. 9 Introducing the IL-12 gene into tumor cells is one strategy with which to avoid the adverse effects of IL-12 in vivo. We introduced the IL-12 gene into a mouse renal cell carcinoma (RenCa) cell line to develop a tumor vaccine and investigated any mechanisms of tumor rejection.
IL-18 was originally identified as IFN-␥-inducing factor, and its cDNA has been cloned from liver extracts of mice with endotoxin shock. 10 Murine recombinant IL-18 (rIL-18) augments NK cell activity in spleen cells and induces IFN-␥ production by stimulated T cells. 10 IL-18 also has in vivo antitumor effects against Meth A sarcoma. 11 These biological activities are similar to those of IL-12. In fact, IL-12 and IL-18 exhibit a remarkably synergistic effect on IFN-␥ induction by stimulated T cells. 12, 13 In this study, we also studied whether IL-18 has a synergistic cancer vaccine effect with local secretion of IL-12 and searched the effector cells involved in the synergism.
MATERIALS AND METHODS

Tumor cell lines
RenCa, a mouse renal cell carcinoma of BALB/c origin, was kindly provided by Dr. Ko Okumura (Juntendo University, Tokyo, Japan) and maintained in Eagle's minimum essential medium supplemented with 5% fetal bovine sera.
Expression vector design and transduction to tumor cells
The expression vector used in this study (pCEXV3) has been described previously.
14 IL-12 is composed of p35 and p40. The cDNAs for these proteins were kindly provided by Dr. Maurice K. Gately (Hoffmann-La Roche, Nutley, NJ) and inserted into the SmaI site of pCEXV3 in the appropriate orientation. These plasmid constructs (pCEXV3/p35, pCEXV3/p40) were cotransduced into the RenCa cell. Briefly, tumor cells (1.8 ϫ 10 5 ) were plated in 60-mm dishes 16 hours before transfection. A total of 9 g of purified pCEXV3 (control) or 7 g of pCEXV3/p35 and 7 g of pCEXV3/p40 were cotransduced with 1 g of purified pSV2neo. 15 The concentration of geneticin (Sigma, St. Louis, Mo) that was used for selection was 1 mg/mL. After selection, colonies were selected and expanded to cell lines.
IL-12 assay
Parental or IL-12 gene-transduced RenCa cells (3 ϫ 10 5 ) were plated in 6-well plates (9.6 cm 2 /well) with 1.5 mL of medium for 24 hours, after which supernatants were collected. IL-12 activity was measured using the lymphoblast proliferation assay. 16 Briefly, human peripheral blood mononuclear cells were isolated by Ficoll-Hypaque gradient centrifugation and subsequently incubated with phytohemagglutinin for 48 hours, followed by human rIL-2 for 24 hours. Phytohemagglutinin blasts (2 ϫ 10 4 ) were then incubated with 50 L of sample supernatants or mouse rIL-12 reference standard for 24 hours. The cells were then pulsed with 1 Ci of [ 3 H]thymidine and cultured for 6 hours. Levels of IL-12 activity in the sample supernatants were calculated by measuring [ 3 H]thymidine incorporation. Results were confirmed using the IL-12 enzyme-linked immunosorbent assay (ELISA) (BioSource International, Camarillo, Calif).
In vivo tumorigenicity of each subline
Syngeneic mice (BALB/c ϩ/ϩ , female, 6 -8 weeks old) and athymic nude mice (BALB/c nu/nu, female, 6 -8 weeks old) were purchased from Clea Japan (Tokyo, Japan). Groups consisted of 5-10 mice throughout all the animal studies. Cells from each subline (1 ϫ 10 6 ) were injected subcutaneously (s.c.) into the flanks of mice. The s.c. tumor growth was measured in millimeters at least three times per week using calipers. The longest surface length (a) and the width perpendicular to this length (b) were measured, and tumor size was reported as a ϫ b. All animal experiments were repeated at least twice to confirm the results and were conducted according to the Guidelines for Animal Experimentation at Kobe University School of Medicine.
In vivo depletion of certain kinds of certain immune cells
A total of 50 L of anti-asialo GM 1 antiserum (Wako, Osaka, Japan) diluted with 150 L of phosphate-buffered saline (PBS) was injected intraperitoneally (i.p.) on day Ϫ1 before tumor challenge and once every 5 days thereafter to deplete NK cells. NK cell depletion was assessed by 4-hour 51 Cr-release assays, with 5000 YAC cells as the target and spleen cells as effector cells at effector to target ratios of 100:1, 50:1, and 25:1. Depletion completely abrogated the detectable NK activity. T cells were depleted in vivo by i.p. administration of the rat monoclonal antibodies (mAbs) GK1.5 (anti-CD4; IgG2b) and 2.43 (anti-CD8; IgG2b) (both hybridomas were acquired from American Type Culture Collection, Manassas, Va). These mAbs were used as ascites fluids (titer of Ͼ1:10,000 according to mouse thymocyte staining by flow cytometry). mAb preparations (0.2 mL) were injected i.p. on day Ϫ3 and every 7 days thereafter. Throughout our experiments, respective T-cell subpopulations were depleted by Ͼ97% according to indirect immunofluorescence staining and cytofluorometric analysis of lymph nodes using mAbs GK1.5 (CD4) or 2.43 (CD8), respectively (data not shown).
Tumor vaccine study (1) s.c. model 
Tumor vaccine study (2) lung metastasis model
RenCa/fibroblast growth factor-2 (FGF-2) is a highly metastatic subline of RenCa transfected with FGF-2 cDNA. 17 These cells (5 ϫ 10 5 cells/mouse) were injected into the tail veins of mice that were injected simultaneously s.c. with MMC-treated parental RenCa or the IL-12-secreting subline (5 ϫ 10 6 cells/mouse). Mice were sacrificed after 2 weeks, and metastatic lung nodules were counted under a dissecting microscope.
Combination therapy of IL-12-secreting RenCa and rIL-18
Murine rIL-18 is a product of Hayashibara Biochemical Laboratories Inc. (Okayama, Japan) and is obtained by expressing murine IL-18 cDNA in Escherichia coli followed by chromatographic purification.
10 IL-18 (1 g) diluted in 0.2 mL of PBS was injected i.p. on day Ϫ1, and treatment was repeated every 3 days until the experiment was completed. Parental RenCa cells (1 ϫ 10 6 cells/mouse) were injected into the right flanks of the mice on day 0. MMC-treated RenCa/IL-12 (5 ϫ 10 6 cells/mouse) was injected into the left flanks simulaneously as a tumor vaccine. In the established tumor experiment, MMCtreated RenCa/IL-12 (5 ϫ 10 6 cells/mouse) was injected s.c. into the left flanks of the mice as a tumor vaccine 3 days after the injection of parental RenCa into the right flanks. In the IL-18 treatment group, IL-18 (1 g) diluted in 0.2 mL of PBS was injected i.p. on day 3; treatment was repeated every 3 days until the experiment was completed. The tumor growth of parental RenCa in the right flanks was measured as described in In vivo tumorigenicity of each subline.
Measurement of sera IFN-␥
The concentration of IFN-␥ in the mouse sera was determined using an ELISA (Amersham, Buckinghamshire, UK) according to the manufacturer's instructions.
RESULTS
IL-12 production by RenCa transduced with the IL-12 gene
The IL-12 activities in the supernatants of a series of transfected clones were measured. Among these, we selected two clones, RenCa/IL-12#1 and RenCa/IL-12#2, for further experiments; both of these clones secreted 50 ng/mL of IL-12 per 10 6 cells per 24 hours. Neither parental RenCa nor RenCa cells transduced with pCEXV3 (RenCa/Con) alone produced detectable amounts of IL-12.
Tumorigenicity of IL-12-secreting RenCa in syngeneic mice
To examine the effect of IL-12 secretion on tumor growth in vivo, 10 6 cells of RenCa/IL-12#1, RenCa/IL-12#2, RenCa/Con, or parental RenCa were injected into the right flanks of syngeneic BALB/c mice. RenCa/ Con and parental RenCa exhibited tumors that proliferated to a similar degree. Alternatively, RenCa/IL-12#1 and RenCa/IL-12#2 were completely rejected (Fig 1) . In the following experiments, RenCa/IL-12#1 and RenCa/IL-12#2 exhibited the same results. Thus, we show representative data of RenCa/IL-12#1, described as RenCa/IL-12.
Effector cells involved in the rejection of RenCa/IL-12
To determine which effector cells are involved in the rejection of IL-12-secreting RenCa, 10 6 parental RenCa or RenCa/IL-12 cells were injected s.c. into nu/nu mice or into nu/nu mice for which NK cell populations had been depleted using an anti asialo-GM 1 polyclonal antibody (Ab). Although RenCa/IL-12 tumor growth in nu/nu mice was retarded compared with parental RenCa, all of the mice eventually developed tumors, suggesting that T cells are involved in the rejection of tumors arising from RenCa secreting IL-12. However, NK cell depletion did not alter the tumorigenicity of RenCa/IL-12#1 in nude mice (Fig 2) . Thus, NK cells do not appear to play an important role in the rejection of RenCa/IL-12.
Tumor vaccine study (1) s.c. model The s.c. injected parental RenCa cells treated with MMC did not affect the tumorigenicity of the parental RenCa injected at the contralateral site. In contrast, both untreated and MMC-treated RenCa/IL-12 inhibited the growth of parental RenCa tumors injected at the contralateral site (Fig 3) . This tumor vaccine effect was abrogated in CD8 ϩ T cell-or in NK cell-depleted mice, whereas the effect was enhanced in CD4 ϩ T cell- depleted mice (Fig 4) . In other words, the effector cells involved in this tumor vaccine effect were CD8 ϩ T cells and NK cells, whereas CD4
ϩ T cells had an inhibitory effect.
Tumor vaccine study (2) lung metastasis model
In the lung metastasis model, we used a highly metastatic subline (RenCa/FGF-2) established by FGF-2 cDNA transduction. When parental RenCa cells treated with MMC were injected s.c., the number of lung metastases of RenCa/FGF-2 significantly decreased. However, s.c. injected RenCa/IL-12 treated with MMC significantly decreased the lung metastases of RenCa/ FGF-2 even further compared with the number of lung metastasis observed in the group treated with MMCtreated parental RenCa cells (Fig 5) .
Synergistic effect of locally secreted IL-12 with systemically administered rIL-18
The systemic administration of rIL-18 alone did not inhibit the tumor growth of parental RenCa. However, this treatment augmented the tumor vaccine effect of RenCa/IL-12 against parental RenCa at the contralateral site (Fig 6) . Moreover, the combination therapy of RenCa/IL-12 and rIL-18 inhibited the established parental RenCa, whereas injection of RenCa/IL-12 alone did not inhibit the established RenCa tumor (Fig 7) . Based on the experiments using immunodeficient mice by Ab treatment, not only CD8 ϩ T cells and NK cells but also CD4 ϩ T cells appear to be involved in the antitumor effect of this combination therapy (Fig 8) . Considering that CD4
ϩ T cells inhibit the tumor vaccine effect of RenCa/IL-12, an additional systemic administration of rIL-18 appears to drastically change the role of CD4 ϩ T cells; this change is closely related to the synergism of RenCa/IL-12 and the systemic administration of rIL-18.
The serum IFN-␥ levels of these mice were determined by ELISA. An s.c. injection of RenCa/IL-12 did not induce serum IFN-␥, whereas the systemic administration of rIL-18 raised serum IFN-␥. There was no difference between rIL-18 and RenCa/IL-12 plus rIL-18, suggesting that the synergistic antitumor effect of RenCa/IL-12 and IL-18 cannot be explained by IFN-␥ production (Fig 9) . Another potentially efficacious cytokine is IL-12, which is a heterodimer of 70 kDa that is formed by two covalently linked glycosylated components of ϳ40 kDa (p40) and 35 kDa (p35).
1 IL-12 exerts a variety of biological effects on T and NK cells in vitro, 20 and its exogenous administration has been shown to have a dramatic effect on the suppression of tumor growth and metastasis. 8 Several investigations have described IL-12 gene transduction, [21] [22] [23] [24] [25] [26] [27] [28] [29] and some have shown that a tumor vaccine based on IL-12-transduced tumor cells is quite effective. We also demonstrated that irradiated RenCa secreting IL-12 suppressed the tumor growth of parental RenCa injected at contralateral sites, whereas irradiated parental RenCa did not. In a previous study, we established RenCa cells secreting IL-2 using the same expression vector. 30 However, these cells did not inhibit the growth of parental RenCa transplanted at a distant site. Moreover, these cells retarded tumor growth in vivo, but did not induce complete rejection. Considering that RenCa cells secreting IL-12 were completely rejected and worked well as a tumor vaccine, IL-12 gene transduction seems to be a better alternative for cancer gene therapy. Rodolfo et al compared IL-12 and IL-2 gene transduction and showed that the transduced IL-12 gene is superior to that of IL-2. 25 The mechanism of the antitumor effect of IL-12 in vivo remains controversial. We demonstrated that T cells are essential for a direct antitumor effect against genetransduced cells, whereas NK cells are not. However, CD8
ϩ T and NK cells seem to be crucial for the vaccination efficacy of cells transduced with the IL-12 gene. We showed that the depletion of CD4 ϩ T cells significantly enhanced vaccination activity. Some investigators have examined the mechanism of vaccination activity associated with cells secreting IL-12. Schmitt et al reported that the depletion of NK cells partially abrogated the vaccination effect and that the simultaneous depletion of CD4 ϩ and CD8 ϩ T cells leads to total abrogation of the antitumor effect, whereas depletion of either CD4 ϩ T or CD8 ϩ T cells alone does not affect the antitumor effect of cells secreting IL-12. 26 Martinotti et al showed the augmented vaccine effect of colon carcinoma cells secreting IL-12 in mice depleted of CD4 ϩ T cells in conjunction with an abundant infiltration of CD8 ϩ T and NK cells in the tumors of these mice. They concluded that CD4 ϩ T cells inhibit the infiltration of CD8 ϩ T and NK cells into tumor sites. 31 We also introduced the IL-12 gene into a mouse malignant melanoma cell line (B16) using the same expression vector. Although IL-12-secreting B16 cells showed retarded tumor growth, they were not completely rejected. However, an in vivo depletion of CD4 ϩ T cells led to complete regression in 60% of the mice. Histological examination showed an abundant infiltration of CD8 ϩ T cells in CD4 ϩ T cell-depleted mice, whereas few CD8 ϩ T cells were infiltrated in nontreated mice (H.N., I.H., T. Horikawa, S.K., and M.I., unpublished observations). Therefore, we assume that NK cells and CD8 ϩ T cells were the main effector cells for the tumor vaccine effect of IL-12-secreting RenCa. Furthermore, CD4
ϩ T cells appear to have an inhibitory effect. IL-18 was originally identified as IFN-␥-inducing factor. 10 Although both IL-12 and IL-18 can act on T cells and induce IFN-␥ production, the pathways of this process are independent. Moreover, IL-18 has a synergistic effect with IL-12 for IFN-␥ production. 10, 12, 13 One explanation for this synergism is the enhanced expression of the IL-18 receptor induced by IL-12. 32 Our present data show that systemic rIL-18 administration enhances the vaccination effect of cells secreting IL-12 against parental cells injected at distant sites, whereas rIL-18 administration alone does not affect the tumor growth of parental RenCa cells. The antitumor effect of this combination therapy is so strong that it inhibited the tumor growth of established parental RenCa cells, whereas IL-12-secreting RenCa alone could not. Thus, combination therapy of IL-12 and IL-18 appears to have clinical efficacy.
To determine the effector mechanism of the combination therapy of IL-12-secreting RenCa and the systemic administration of rIL-18, we performed in vivo depletion experiments. Our results showed that in addition to CD8 ϩ T cells and NK cells, CD4 ϩ T cells were essential for the antitumor effect. In fact, Micallef et al showed that the cytolytic activity of splenocytes from mice treated with IL-18 and rejected Meth A sarcoma is inhibited by anti-CD4 mAb and complement in vitro. They concluded that the cells responsible for the cytotoxic activity induced by IL-18 were CD4 ϩ T cells. 11 Dao et al also showed that IL-18 selectively enhances the Fas ligand-mediated cytotoxicity of T helper 1 cells. 33 Considering these reports and our data, CD4 ϩ T cells appear to be essential for the antitumor effects of IL-18. CD4 ϩ T cells have an inhibitory effect against the tumor vaccine of IL-12-secreting RenCa, whereas they act as effector cells when rIL-18 is administered. The synergistic cancer vaccine effect of an in situ secretion of IL-12 and the systemic administration of rIL-18 may be ascribed to the functional change of CD4 ϩ T cells. We measured the serum IFN-␥ levels of these mice. Systemically administered rIL-18 induced serum IFN-␥, whereas RenCa secreting IL-12 did not. The serum IFN-␥ level of the IL-18 group and the IL-18 plus RenCa/IL-12 group was the same. Therefore, no synergistic effect of IL-18 and RenCa/IL-12 on IFN-␥ production was observed, although elevated serum IFN-␥ may participate in the synergistic antitumor effects of IL-18 plus RenCa/IL-12.
In conclusion, cells transduced with the IL-12 gene were completely rejected in syngeneic mice but not in athymic nude mice. Cells secreting IL-12 can also work as a tumor vaccine; CD8 ϩ T and NK cells were essential for this tumor vaccine effect, whereas CD4 ϩ T cells had an inhibitory effect. The tumor vaccine effect of IL-12-secreting RenCa was enhanced by the systemic administration of rIL-18, and this combination therapy can retard even an established tumor. Furthermore, in addition to CD8 ϩ T cells and NK cells, CD4 ϩ T cells also appear to be essential for the tumor vaccine effect of the combination therapy. This functional change of CD4 ϩ T cells may explain the synergistic antitumor effects of IL-12 and IL-18.
